Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | HINT1 | P49773 | 4/20 | 0.51 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 4/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.45 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33190 | 1.00 | NT5E (0.53) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL12015141 | 1.00 | NT5E (0.53) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL21344309 | 0.93 | NT5E (0.55) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL12590116 | 0.92 | NT5E (0.51) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL12646734 | 0.92 | NT5E (0.51) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL12015169 | 0.92 | NT5E (0.51) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL17461707 | 0.92 | NT5E (0.54) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL12646612 | 0.91 | NT5E (0.60) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL12590132 | 0.91 | NT5E (0.60) | NT5ETGM2HINT1FUT5TAS1R3 | |
| SCHEMBL12015188 | 0.91 | NT5E (0.60) | NT5ETGM2HINT1FUT5TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-9657050-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Masafumi, Matsuo (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657049-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Matsuo, Masafumi (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657049-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Matsuo, Masafumi (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657050-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Masafumi, Matsuo (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| EP-2530153-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2530154-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2530155-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2135948-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-8624019-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2014-01-07 | — | — | US | disclosed |
| US-8624019-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20130090465-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
| US-20130090465-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| US-7902160-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | MASAFUMI MATSUO (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | MASAFUMI MATSUO (JP) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | NT5E 963/4885TGM2 2068/4885HINT1 2496/4885 |
| US-20130090465-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | SNRPA, RBM17, SNRPA1 | NT5E 154/4885TGM2 3530/4885HINT1 2641/4885 |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | NSUN2, TRDMT1, POLRMT | NT5E 266/4885TGM2 3881/4885HINT1 2069/4885 |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | SNRPA, RBM17, SNRPA1 | NT5E 155/4885TGM2 3561/4885HINT1 2656/4885 |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | SNRPA, RBM17, SNRPA1 | NT5E 155/4885TGM2 3561/4885HINT1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.